GRIP Molecular Technologies, Inc
Edward Gillen is the Chief Executive Officer and Board Director at GRIP Molecular Technologies, Inc, developing an electronic biosensor for lab-grade diagnostic results. Previously, he served as the Chief Executive Officer, President, and Board Director at Medality Medical, focusing on surgical reversal of type 2 diabetes. Prior to that, he held various leadership roles at BD in the Diabetes Care Division and Pharmaceutical Systems Division. Edward has a MBA in Marketing and Management from Penn State University and a BS in Management from William Paterson University of New Jersey.
This person is not in any teams
GRIP Molecular Technologies, Inc
GRIP Molecular is developing a novel, patent-protected, chip-based electronic biosensor that will provide lab-grade diagnostic results in minutes using a mobile device at the point of need. Unlike existing diagnostic technologies, it has the capability to simultaneously detect various diseases and characterize their state of infection (infectious to immune) with a single test. GRIP uses a combination of novel nanomaterials and patented 3D printing to deliver accurate results in minutes without the burden of complex chemistry. The appearance of COVID-19 as a global health threat has increased the urgency to transform diagnostics, which the GRIP team was well into even before this threat emerged. The ability to quickly, easily and cost-effectively test for active infection and immunity at the point of need has become the new baseline for what we should expect for early detection of all kinds of disease, but particularly when fighting a pandemic level enemy. GRIP is committed to confirm the science and commercialize a new approach with a number of specific panels/products that address our most challenging diseases and chronic conditions.